/cdn.vox-cdn.com/uploads/chorus_asset/file/24016885/STK093_Google_04.jpg)
/cdn.vox-cdn.com/uploads/chorus_asset/file/24808816/Starfield__The_Settled_Systems___Supra_Et_Ultra_____Starfield__The_Settled_Systems___Supra_Et_Ultra_2023_7_25_94252.263_1440p_streamshot.png)
Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which will be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP at a price of €35 per share, representing a total equity value of approximately € represents. 154 million.
BIOCORP is a French company specializing in the design, development and manufacture of delivery systems and innovative medical devices, including Malya, a Bluetooth enabled smart add-on device for pen injectors.
Starting in 2021 the companies are collaborating on the development and commercialization of the Mallya add-on device for the Novo Nordisk FlexTouch pen to be used by people with diabetes, and expanding this collaboration to develop versions of the Mallya device during 2022 and 2023 Has been done to other medical fields.
Marianne Olholm, Senior Vice President, Devices and Delivery Solutions at Novo Nordisk, said: “Novo Nordisk has strong and established core capabilities within the development, scaling up and mass manufacturing of innovative injection devices for insulin and other drugs, and we Seeking to increase agility to enable rapid innovation and development of novel connected devices. We have enjoyed a fruitful association with BIOCORP over the past few years, and we look forward to continuing to serve the company and its highly skilled workforce. Novo Nordisk will complement our in-house efforts within connected delivery solutions and accelerate our ambitions within devices and delivery solutions.
Following the acquisition, Novo Nordisk aims to retain BIOCORP’s agility and entrepreneurial spirit, while integrating the organization with the goal of delivering cutting-edge devices and delivery solutions to improve care for people worldwide suffering from serious chronic diseases. And invest.
“We are delighted at the prospect of joining Novo Nordisk, a leading global healthcare company. This potential combination rewards our efforts, launched five years ago, to digitize the treatment and monitoring of chronic patients, transform their daily lives With the continued purpose of simplifying, our teams are excited to advance this public health mission, fueled by the strength of Novo Nordisk’s global presence.
